ct-388 peptide CT - CT-388structure CT388 CT-388: A Promising Dual Receptor Agonist for Obesity and Type 2 Diabetes

CT-996 The investigational peptide known as CT-388, developed by Roche, is emerging as a significant contender in the treatment of obesity and type 2 diabetes (T2D). This novel therapeutic agent functions as a dual agonist, selectively activating both the glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors.Effects of CT-388, a once-weekly signaling-biased dual ... This dual mechanism of action is designed to offer enhanced efficacy in managing weight and improving metabolic dysfunction, positioning CT-388 as a potentially groundbreaking treatment option.

CT-388 is being developed as a once-weekly subcutaneous injectable therapy. This once-weekly injectable therapy aims to simplify treatment regimens and improve patient adherence. Early research, including preclinical studies in mice and monkeys, has demonstrated that CT-388 improved glycemic control in mice and monkeys, and reduced bodyweight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis.2024年5月17日—在具有前期糖尿病的患者子族群中，CT-388治療使所有患者的血糖恢復正常，顯示出藥物對血糖平衡的效果。此外，CT-388的安全性和耐受性與其藥物類別一致，治療 ... These findings provide a strong foundation for its subsequent clinical trials.

The search_keyword CT-388 has garnered considerable attention due to its impressive performance in recent clinical studies.Petrelintide / CT-388 - Pipeline - Zealand Pharma Roche's dual GLP-1\/GIP receptor agonist CT-388 has produced positive findings in its Phase Ib clinical trial and significant results in its Phase II clinical trial. Topline results from the CT388-103 study indicated that a 24mg dose of CT-388 enabled 54 percent of participants to attain resolution of obesity. Furthermore, data from a Phase II trial showed Roche's CT-388 shows promising results with 22.5% weight loss. At 48 weeks, adults with obesity treated with CT-388 (Roche) experienced up to 22.5% weight loss. This level of efficacy demonstrates the drug's potential to induce substantial and clinically meaningful weight reduction.

Beyond weight loss, CT-388 also shows promise in improving glycemic control, a critical factor for individuals with type 2 diabetes.1天前—Roche's CT-388 shows promising results with 22.5% weight lossin a phase 2 trial, advancing obesity treatment options significantly. In participants with pre-existing diabetes, CT-388 treatment led to the normalization of blood glucose levels, highlighting its dual therapeutic benefits. The CE-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4-week treatment period in participants with metabolic conditions. This is consistent with the dual receptor modulation mechanism of CT-388, targeting both appetite regulation and glucose metabolism作者：E Melson·2025·被引用次数：324—75-LB:CT-388, A novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four ....

The development of CT-388 is part of a broader landscape of advancements in incretin-based medications. While the exact CT-388 structure is proprietary, its function as a dual agonist positions it alongside other prominent therapies targeting the GLP-1 and GIP receptors. CT-388 is a peptide designed to activate the GLP-1 and GIP receptors, the same targets engaged by established treatments like Eli Lilly's Zepbound. However, CT-388's unique signaling-biased approach may offer distinct advantages. CT-388 is a once-weekly subcutaneous dual glucagon-like peptide 1 (GLP-1) and GIP receptor agonist, indicating a sophisticated design aimed at optimizing therapeutic outcomes.

Clinical trials for CT-388 are ongoing and expandingRoche, trailing in obesity, showcases new data for GLP-1 .... A multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study is evaluating the efficacy and safety of CT-388 at various dosages. CT-388 will be administered subcutaneously (SC) once weekly as part of these studies.Petrelintide / CT-388 - Pipeline - Zealand Pharma The CT-388 clinical trial program includes various phases, with CT-388 Phase 3 testing anticipated before the end of March, signifying Roche's commitment to advancing this candidate rapidly. While this puts CT-388 years behind some existing treatments, its unique profile suggests it could capture a significant share of the marketGenentech reports positive trial results for obesity treatment. Roche's CT-388 Phase 2 showed competitive 48-week weight loss, further strengthening its market position.

In summary, CT-388 represents a significant advancement in the pharmacological treatment of obesity and type 2 diabetes. Its mechanism as a dual GLP-1/GIP receptor agonist, its convenient once-weekly subcutaneous administration, and its demonstrated efficacy in promoting weight loss and improving glycemic control make it a highly anticipated therapeutic agentRoche's GLP1/GIP drug sees 22.5% weight loss, readies .... The CT-388 development pathway, including its progression into CT-388 Phase 3 trials, underscores its potential to reshape the treatment landscape for these widespread metabolic conditions.Roche GLP-1 produces “robust” weight loss in phase II ... The CT-388 drug, a peptide, is undergoing rigorous investigation to solidify its role in future obesity and diabetes management.Roche's Obesity Drug Shows 22.5% Weight Loss in Phase ...